ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

Taxol Released On Compassionate Use Basis To Centers; Ohio, Columbia Begin Treatments

October 18, 1991

Obey Says NCI “Must Do Better,” Response Dispute GAO Conclusion

August 8, 1980

Regulatory Agencies: FDA To Increase Fees For Mammography Facility Inspections

January 30, 1998

High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I

April 27, 2001

CPRIT Sets Funding Priorities For Rare and Pediatric Cancers

November 14, 2014

New Jersey Insurers To Cover Patient Care Costs In Trials.

January 14, 2000